Literature DB >> 20005305

Structure-guided expansion of kinase fragment libraries driven by support vector machine models.

Jon A Erickson1, Mary M Mader, Ian A Watson, Yue W Webster, Richard E Higgs, Michael A Bell, Michal Vieth.   

Abstract

This work outlines a new de novo design process for the creation of novel kinase inhibitor libraries. It relies on a profiling paradigm that generates a substantial amount of kinase inhibitor data from which highly predictive QSAR models can be constructed. In addition, a broad diversity of X-ray structure information is needed for binding mode prediction. This is important for scaffold and substituent site selection. Borrowing from FBDD, the process involves fragmentation of known actives, proposition of binding mode hypotheses for the fragments, and model-driven recombination using a pharmacophore derived from known kinase inhibitor structures. The support vector machine method, using Merck atom pair derived fingerprint descriptors, was used to build models from activity from 6 kinase assays. These models were qualified prospectively by selecting and testing compounds from the internal compound collection. Overall hit and enrichment rates of 82% and 2.5%, respectively, qualified the models for use in library design. Using the process, 7 novel libraries were designed, synthesized and tested against these same 6 kinases. The results showed excellent results, yielding a 92% hit rate for the 179 compounds that made up the 7 libraries. The results of one library designed to include known literature compounds, as well as an analysis of overall substituent frequency, are discussed. Copyright 2009 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2009        PMID: 20005305     DOI: 10.1016/j.bbapap.2009.12.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

2.  Idea2Data: Toward a New Paradigm for Drug Discovery.

Authors:  Christos A Nicolaou; Christine Humblet; Hong Hu; Eva M Martin; Frank C Dorsey; Thomas M Castle; Keith Ian Burton; Haitao Hu; Jorg Hendle; Michael J Hickey; Joel Duerksen; Jibo Wang; Jon A Erickson
Journal:  ACS Med Chem Lett       Date:  2019-02-04       Impact factor: 4.345

3.  Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.

Authors:  Chenxiao Da; Dehui Zhang; Michael Stashko; Eleana Vasileiadi; Rebecca E Parker; Katherine A Minson; Madeline G Huey; Justus M Huelse; Debra Hunter; Thomas S K Gilbert; Jacqueline Norris-Drouin; Michael Miley; Laura E Herring; Lee M Graves; Deborah DeRyckere; H Shelton Earp; Douglas K Graham; Stephen V Frye; Xiaodong Wang; Dmitri Kireev
Journal:  J Am Chem Soc       Date:  2019-09-20       Impact factor: 15.419

4.  Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.

Authors:  Dilip Narayanan; Osman A B S M Gani; Franz X E Gruber; Richard A Engh
Journal:  J Cheminform       Date:  2017-07-04       Impact factor: 5.514

5.  De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.

Authors:  Robert Urich; Grant Wishart; Michael Kiczun; André Richters; Naomi Tidten-Luksch; Daniel Rauh; Brad Sherborne; Paul G Wyatt; Ruth Brenk
Journal:  ACS Chem Biol       Date:  2013-03-27       Impact factor: 5.100

6.  Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

Authors:  Everett J Perkins; Maria Posada; P Kellie Turner; Jill Chappell; Wee Teck Ng; Chris Twelves
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.